Profile data is unavailable for this security.
About the company
Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
- Revenue in EUR (TTM)0.00
- Net income in EUR-14.76m
- Incorporated2006
- Employees19.00
- LocationGeneuro SA3, Chemin du Pre-FleuriPLAN-LES-OUATES 1228SwitzerlandCHE
- Phone+41 225524800
- Fax+41 227945086
- Websitehttps://www.geneuro.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Predilife SA | 317.79k | -4.22m | 23.44m | 19.00 | -- | -- | -- | 73.75 | -1.14 | -1.14 | 0.0858 | -1.06 | 0.0695 | -- | 2.05 | 17,030.55 | -92.43 | -89.36 | -129.39 | -123.81 | 97.25 | 83.94 | -1,329.21 | -1,901.22 | -- | -6.23 | 2.20 | -- | 10.11 | 79.85 | -15.58 | -- | -18.51 | -- |
| Oncodesign Precision Medicine Opm SA | 1.07m | -8.09m | 26.92m | 22.00 | -- | 6.67 | -- | 25.11 | -0.4863 | -0.4863 | 0.0645 | 0.2219 | 0.0613 | -- | 1.39 | 48,735.00 | -46.23 | -- | -63.87 | -- | 130.48 | -- | -754.61 | -- | -- | -- | 0.7052 | -- | -86.57 | -- | -3,399.73 | -- | -- | -- |
| Fermentalg SA | 4.06m | -14.15m | 28.11m | 57.00 | -- | 0.7209 | -- | 6.93 | -0.3233 | -0.3233 | 0.0932 | 0.7213 | 0.0753 | 0.533 | 3.35 | -- | -24.63 | -21.94 | -26.79 | -24.71 | 13.21 | 14.73 | -327.08 | -248.95 | 3.53 | -63.30 | 0.3323 | -- | -46.94 | 75.18 | -43.29 | -- | -11.01 | -- |
| Groupe Berkem SA | 51.94m | 367.00k | 29.85m | 234.00 | 28.33 | -- | 6.72 | 0.5747 | 0.0593 | 0.0593 | 2.92 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 55.32 | -- | 0.7065 | -- | -- | 1.39 | -- | -- | 0.733 | -- | 123.42 | -- | -- | -- |
| Poxel SA | 1.55m | -44.24m | 30.05m | 30.00 | -- | -- | -- | 19.44 | -1.44 | -1.44 | 0.0507 | -1.22 | 0.0597 | -- | 5.42 | 30,920.00 | -170.71 | -31.97 | -432.50 | -55.94 | 0.1294 | -- | -2,861.58 | -101.47 | -- | -4.08 | 11.28 | -- | -94.97 | -33.77 | -32.13 | -- | -8.49 | -- |
| Gensight Biologics SA | 1.27m | -26.22m | 30.96m | 16.00 | -- | -- | -- | 24.43 | -0.5427 | -0.5427 | 0.0269 | -0.4726 | 0.0723 | -- | 2,534.00 | 79,187.50 | -149.52 | -79.44 | -- | -144.54 | -- | -- | -2,069.53 | -1,036.27 | -- | -- | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| Global Bioenergies SA | 3.25m | -8.66m | 33.45m | 46.00 | -- | 3.21 | -- | 10.29 | -0.4797 | -0.4797 | 0.1802 | 0.5743 | 0.1632 | 5.21 | 65.62 | 70,638.05 | -43.47 | -43.66 | -64.54 | -82.47 | -153.20 | -948.35 | -266.41 | -1,331.36 | 3.54 | -- | 0.2626 | -- | 365.83 | 36.25 | 27.78 | -- | -19.49 | -- |
| Abionyx Pharma SA | 4.75m | -3.90m | 34.47m | 63.00 | -- | 6.25 | -- | 7.26 | -0.1382 | -0.1382 | 0.1683 | 0.17 | 0.2968 | 28.49 | 4.18 | -- | -24.39 | -- | -38.01 | -- | 11.22 | -- | -82.19 | -- | 0.9785 | -3,882.00 | 0.4732 | -- | -- | -- | -- | -- | -- | -- |
| genOway SA | 18.63m | 1.59m | 39.60m | 124.00 | 23.54 | 2.32 | 9.87 | 2.13 | 0.1814 | 0.1814 | 2.12 | 1.84 | 0.5813 | 0.3881 | 2.50 | 142,180.80 | 4.98 | -0.5615 | 6.72 | -0.8058 | 97.61 | 93.72 | 8.56 | -1.12 | 2.10 | 17.42 | 0.3344 | -- | 21.64 | 11.57 | 341.09 | -16.63 | -18.02 | -- |
| Biosynex SA | 93.05m | -13.79m | 42.98m | 560.00 | -- | -- | -- | 0.4619 | -1.94 | -1.94 | -- | -- | -- | -- | -- | 248,141.30 | -- | 25.60 | -- | 33.90 | 25.22 | 51.82 | -13.15 | 20.26 | -- | -4.45 | -- | 14.72 | -48.61 | 45.12 | -84.99 | 118.26 | -- | -- |
| GeNeuro SA | 0.00 | -14.76m | 43.45m | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| AbL Diagnostics SA | 11.19m | 1.20m | 49.31m | 19.00 | 5.10 | 7.35 | 162.52 | 4.41 | 0.5997 | 0.5997 | 5.58 | 0.4165 | 1.18 | -- | 5.21 | 588,990.50 | 12.67 | 8.99 | 26.09 | 10.77 | 35.76 | 38.29 | 10.75 | 31.17 | 1.28 | -- | 0.31 | 0.00 | -- | 67.89 | 328.77 | -- | -- | -- |
Data as of May 07 2024. Currency figures normalised to Geneuro SA's reporting currency: Euro EUR
1.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Financi�re Arbevel SAas of 30 Dec 2022 | 415.58k | 1.40% |
| Invesco Advisers, Inc.as of 31 Dec 2023 | 34.89k | 0.12% |
| Aviva Investors Global Services Ltd.as of 15 Apr 2021 | 21.35k | 0.07% |
Data from 31 Dec 2023 - 28 Mar 2024Source: FactSet Research Systems Inc.
